cassava alzheimer news - Search News

What’s left in Cassava

The New York Times · 1d

Trial of Controversial Alzheimer’s Drug Halted After Disappointing Results

Cassava Sciences said that its drug did not significantly reduce cognitive decline in 1,900 people with mild to moderate Alzheimer’s disease.

Seeking Alpha · 17h

What’s left in Cassava after Phase 3 setback for Alzheimer’s drug

Cassava Sciences (SAVA) stock faces uncertainty after a major late-stage trial setback for the company's Alzheimer's candiate simufilam. Read more here.

Hosted on MSN · 1d

Cassava shares sink on plans to stop Alzheimer's drug studies

(Reuters) -Cassava Sciences said it will stop all trials of its Alzheimer's disease drug after it failed a late-stage study, sending shares of the drug developer plummeting 83% in early trading on Monday.

6h

A Controversial Alzheimer’s Drug Has Gone Down in Flames

Cassava Sciences' simufilam failed a Phase III trial for Alzheimer's disease, likely marking the end of a drug surrounded by ...

1d

Cassava Sciences Alzheimer's Drug Fails To Hit Primary Goal In Pivotal Study, Pharma Halts Late-Stage Studies

Cassava Sciences Inc. (NASDAQ:SAVA) stock plunged Monday after the company released topline data from the Phase 3 ReThink-ALZ ...

pharmaphorum23h

End looms for Cassava's simufilam in Alzheimer's disease

Cassava Sciences' troubled development of Alzheimer's disease candidate simufilam looks like it may have finally reached the ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results